123408-74-2 ((C14 Ceramide (d18:1/14:0))

N-myristoyl-D-erythro-sphingosine;N-tetradecanoylsphing-4-enine;C14 Ceramide (d18:1/14:0), N-myristoyl-D-erythro-sphingosine, powder;N-(Tetradecanoyl)-sphing-4-enine;N-(tetradecanoyl)sphing-4-enine;J-019511;N-tetradecanoylsphingosine;1ST174855-100M;N-(myristoyl)ceramide;34227-72-0;C14 Ceramide;26549-44-0;AS-56316;C14 Ceramide (d18:1/14:0);MFCD01320386;BP-28813;C14-Ceramide;N-myristoylsphingosine;CHEBI:72957;C14Ceramide;Cer(d18:1/14:0);LMSP02010001;N-myristoylsphing-4-enine;Tetradecanamide, N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-, rel-;CHEBI:34863;SCHEMBL8797590;C14 Cer;123408-74-2;N-Myristoyl-D-sphingosine, >=98.0% (TLC);N-[(1S,2R,3E)-2-Hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]tetradecanamide;N-(myristoyl)-ceramide;N-[(2S,3R,4E)-1,3-dihydroxyoctadec-4-en-2-yl]tetradecanamide;Tetradecanamide, N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-, [R-(R*,S*)]-;Tetradecanamide,N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-,rel-;N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]tetradecanamide;C14 Ceramide Solution in Methanol, 100ug/mL;N-(tetradecanoyl)-ceramide;GF5K64LH95;Tetradecanamide, N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-;N-(tetradecanoyl)ceramide;AKOS037645031;YEA40874;FC19602;MSK174855-100M;N-Myristoyl-D-sphingosine;N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]tetradecanamide;N-[2-hydroxy-1-(hydroxymethyl)-3- heptadecenyl]-, [R-[R*,S*-(E)]]tetradecanamide;HY-124177;

ZKRPGPZHULJLKJ-JHRQRACZSA-N

1S/C32H63NO3/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-31(35)30(29-34)33-32(36)28-26-24-22-20-17-14-12-10-8-6-4-2/h25,27,30-31,34-35H,3-24,26,28-29H2,1-2H3,(H,33,36)/b27-25+/t30-,31+/m0/s1

O[C@H](/C=C/CCCCCCCCCCCCC)[C@H](CO)NC(CCCCCCCCCCCCC)=O